The provisions of the Inflation Reduction Act of 2022 (IRA) for controlling Medicare drug costs could have broad impacts, affecting not only pharmaceutical manufacturers, but also stakeholders across the industry. Explore the major components of the IRA’s drug pricing provisions and potential implications. We’ll discuss:

• Regulatory guidance and implementation deadlines for price negotiation and rebate policies
• The strategic choices around Medicare Part D benefit redesign and Coverage & Reimbursement for Insulin, Vaccines, Low Income Subsidies, and Biosimilars